In establishing these rules, a distinction should be made between investigational medicinal products (the tested product and its reference products, including placebos) and auxiliary medicinal products (medicinal products used in the context of a clinical trial but not as investigational medicinal products), such as medicinal products used for background treatment, challenge agents, rescue medication, or used to assess end-points in a clinical trial.

Farmed animals in the EU are fed with roughage, feed materials and compound feed (mixture of feed materials). If animals are sick and need a treatment, veterinary medicinal products may be administered on the basis of a veterinary prescription.

The EU’s pharmaceutical and healthcare related, including medical devices , industries are world-leading sectors that play an essential role in finding new medical treatments and medicines and improving the health and quality of life of EU citizens, in particular of the ageing population.

As part of the sub-project within RESTART BOA e.V. wants to enable 30 addicted women living with drug substitutes to integrate into working life by means of tailor-made assistance and qualification.

- Technological platforms for the developments in the fields of new diagnostic, prevention and therapeutic tools: In the context of preventing and treating diseases, the objectives are to foster academic and industrial collaboration through technological platforms where multidisciplinary approaches using cutting edge technologies arising from genomic research may contribute to health care progress and cost reduction through more precise diagnosis, individualised treatment and more efficient development pathways for new drugs and therapies (such as the selection of new drug candidates), and other novel products of the new technologies.

- Technological platforms for the developments in the fields of new diagnostic, prevention and therapeutic tools: In the context of preventing and treating diseases, the objectives are to foster academic and industrial collaboration through technological platforms where multidisciplinary approaches using cutting edge technologies arising from genomic research may contribute to health care progress and cost reduction through more precise diagnosis, individualised treatment and more efficient development pathways for new drugs and therapies (such as the selection of new drug candidates), and other novel products of the new technologies.